Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection
Immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is
central to long-term control of the current pandemic. Despite our rapidly advancing …
central to long-term control of the current pandemic. Despite our rapidly advancing …
Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals after mRNA vaccination
mRNA vaccines for SARS-CoV-2 have been authorized for emergency use. Despite their
efficacy in clinical trials, data on mRNA vaccine–induced immune responses are mostly …
efficacy in clinical trials, data on mRNA vaccine–induced immune responses are mostly …
Durability of immunity to SARS-CoV-2 and other respiratory viruses
Even in nonpandemic times, respiratory viruses account for a vast global burden of disease.
They remain a major cause of illness and death and they pose a perpetual threat of breaking …
They remain a major cause of illness and death and they pose a perpetual threat of breaking …
Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the global
COVID-19 pandemic. Rapidly spreading SARS-CoV-2 variants may jeopardize newly …
COVID-19 pandemic. Rapidly spreading SARS-CoV-2 variants may jeopardize newly …
[HTML][HTML] Glucocorticoids and B cell depleting agents substantially impair immunogenicity of mRNA vaccines to SARS-CoV-2
Background: Individuals with chronic inflammatory diseases (CID) are frequently treated with
immunosuppressive medications that can increase their risk of severe COVID-19. While …
immunosuppressive medications that can increase their risk of severe COVID-19. While …
Persistence of antibody and cellular immune responses in coronavirus disease 2019 patients over nine months after infection
L Yao, GL Wang, Y Shen, ZY Wang… - The Journal of …, 2021 - academic.oup.com
Background The duration of humoral and T and B cell response after the infection of severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains unclear. Methods We …
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains unclear. Methods We …
Twelve-month specific IgG response to SARS-CoV-2 receptor-binding domain among COVID-19 convalescent plasma donors in Wuhan
C Li, D Yu, X Wu, H Liang, Z Zhou, Y Xie, T Li… - Nature …, 2021 - nature.com
To investigate the duration of humoral immune response in convalescent coronavirus
disease 2019 (COVID-19) patients, we conduct a 12-month longitudinal study through …
disease 2019 (COVID-19) patients, we conduct a 12-month longitudinal study through …
[HTML][HTML] SARS-CoV-2 variants show resistance to neutralization by many monoclonal and serum-derived polyclonal antibodies
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the global
COVID-19 pandemic infecting more than 106 million people and causing 2.3 million deaths …
COVID-19 pandemic infecting more than 106 million people and causing 2.3 million deaths …
Long-term persistence of anti-SARS-COV-2 IgG antibodies
Antibodies against severe acute respiratory syndrome coronavirus-2 (Anti-SARS-COV-2)
can be detected in patients with COVID-19 in 7 to 10 days post onset of symptoms (POS) …
can be detected in patients with COVID-19 in 7 to 10 days post onset of symptoms (POS) …
[HTML][HTML] Longitudinal analysis reveals distinct antibody and memory B cell responses in SARS-CoV2 naive and recovered individuals following mRNA vaccination
Novel mRNA vaccines for SARS-CoV2 have been authorized for emergency use and are
currently being administered to millions of individuals worldwide. Despite their efficacy in …
currently being administered to millions of individuals worldwide. Despite their efficacy in …